{"id":68421,"date":"2025-09-16T22:18:07","date_gmt":"2025-09-16T22:18:07","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/68421\/"},"modified":"2025-09-16T22:18:07","modified_gmt":"2025-09-16T22:18:07","slug":"is-the-novo-nordisk-stock-death-spiral-finally-over-novo-nordisk-nysenvo","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/68421\/","title":{"rendered":"Is The Novo Nordisk Stock Death Spiral Finally Over? &#8211; Novo Nordisk (NYSE:NVO)"},"content":{"rendered":"<p class=\"block core-block\"><strong>Novo Nordisk A\/S\u00a0<\/strong>NVO is trading higher on Friday. It is just below resistance around the $58 level.<\/p>\n<p class=\"block core-block\">Novo has been in a major downtrend since June 2024. Since then, it has lost about 60% of its value. But there is a chance that a reversal may be taking place. This is why it is our <a href=\"https:\/\/www.benzinga.com\/topic\/stock-of-the-day\" target=\"_blank\" rel=\"nofollow noopener\">Stock of the Day<\/a>.<\/p>\n<p class=\"block core-block\">Sometimes traders and investors forget the basic principles of financial markets and overcomplicate things. One of these principles is that prices are determined by supply and demand.<\/p>\n<p class=\"block core-block\">If a stock is in a downtrend, it&#8217;s because there are more shares available for sale than there are buyers. Sellers undercut each other&#8217;s prices to attract buyers, which in turn pushes the stock lower.<\/p>\n<p class=\"block core-block\">At support levels, there is a large amount of buy interest. There are as many, or even more shares to be bought than there are for sale. This is why a selloff will end or pause when it reaches support.<\/p>\n<p class=\"block core-block\"><strong>Read Also:<\/strong> <a href=\"https:\/\/www.benzinga.com\/news\/politics\/25\/09\/47688156\/trump-wants-to-end-quarterly-reporting-requirements-not-everyone-agrees\" target=\"_blank\" rel=\"nofollow noopener\"><strong>Trump Wants To End Quarterly Reporting Requirements\u2014Not Everyone Agrees<\/strong><\/a><\/p>\n<p class=\"block core-block\">As you can see on the chart below, this is what happened with Novo Nordisk in April around the $58 level.<\/p>\n<p>Novo technical analysis<\/p>\n<p class=\"block core-block\">After finding support, the stock rallied. People who bought shares at the support were happy they did so.<\/p>\n<p class=\"block core-block\">But in July, the support broke, and the stock dropped below it. When this happened, a number of the people who purchased shares regretted doing so. Many decided to sell their stock if they could eventually do so without losing money.<\/p>\n<p class=\"block core-block\">Now that the stock has rallied back to this level, these unhappy buyers are placing sell orders. This will allow them to finally exit their positions at breakeven.<\/p>\n<p class=\"block core-block\">There are so many of these orders that it has created resistance.<\/p>\n<p class=\"block core-block\">If the buyers can eventually overpower the sellers and the resistance breaks, it could be the beginning of a new uptrend. It will show that the sellers who created the resistance have left the market. They have either canceled or finished their orders.<\/p>\n<p class=\"block core-block\">With this large amount of supply off the market, the stock may be positioned to move higher. The long downtrend may finally be over.<\/p>\n<p class=\"block core-block\"><strong>Read Next:<\/strong> <\/p>\n<p class=\"block core-block\">Image: Shutterstock<\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk A\/S\u00a0NVO is trading higher on Friday. It is just below resistance around the $58 level. Novo&hellip;\n","protected":false},"author":2,"featured_media":68422,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[275],"tags":[47665,10752,5324,18,135,475,474,19,17,5323,10753,47666,47667,47668],"class_list":{"0":"post-68421","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-category-technicals","9":"tag-category-trading-ideas","10":"tag-cms-wordpress","11":"tag-eire","12":"tag-health","13":"tag-health-care","14":"tag-healthcare","15":"tag-ie","16":"tag-ireland","17":"tag-pageisbzpro-bz","18":"tag-symbol-nvo","19":"tag-tag-healthcare","20":"tag-tag-pharmaceuticals","21":"tag-tag-stock-of-the-day"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/68421","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=68421"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/68421\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/68422"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=68421"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=68421"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=68421"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}